TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33971289
Drug: Nonuse of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonuse of β-blockers (Control)
Study: 33754794
Drug: NT-proBNP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP levels ≤1000 pg/mL in obese patients
Study: 33754794
Drug: NT-proBNP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP levels ≤1000 pg/mL in nonobese patients
Study: 33026823
Drug: Atropine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (15 mcg/kg) administered intravenously
Study: 32091400
Drug: One-month P2Y12
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-month P2Y12 inhibitor therapy
Study: 32091400
Drug: Six-month P2Y12
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-month P2Y12 inhibitor therapy
Study: 33865446
Drug: Lecanemab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecanemab (10 mg/kg biweekly)
Study: 34581430
Drug: VASP-guided ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VASP-guided ticagrelor dosing
Study: 36293912
Drug: Beer (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beer (350 mL)
Study: 36293912
Drug: Water (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (350 mL)
Study: 33541567
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training + Eurycoma longifolia
Study: 33541567
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training + placebo
Study: 36170688
Drug: High-dose glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucocorticoids (methylprednisolone 10 mg/kg)
Study: 34480563
Drug: Standard-dose glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose glucocorticoids (dexamethasone 8 mg)
Study: 32049923
Drug: 0.005% estriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% estriol vaginal gel
Study: 35230622
Drug: Direct‐to‐patient message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct‐to‐patient message through the EHR portal with HCV antibody lab order
Study: 35085877
Drug: Oxycodone/acetaminophen (Oxy)
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone/acetaminophen (Oxy)
Study: 37654895
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP)
Study: 35179251
Drug: Fostamatinib 150
Normalized name: fostamatinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 150 mg BID orally
Study: 32585741
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of pinprick therapy with super pulse fractional CO2 laser
Study: 35829935
Drug: Abemaciclib 150
Normalized name: abemaciclib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 150 mg and Tamoxifen 20 mg (A + T)
Study: 35829935
Drug: Abemaciclib 150
Normalized name: abemaciclib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 150 mg (A-150)
Study: 35829935
Drug: Abemaciclib 200
Normalized name: abemaciclib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 200 mg and prophylactic loperamide (A-200)
Study: 33197225
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (sorafenib or lenvatinib)
Study: 33197225
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitor (second-line therapy)
Study: 33197225
Drug: Cabozantinib, regorafenib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib, regorafenib, ramucirumab, atezo + bev (second-line therapy)
Study: 33197225
Drug: Pembrolizumab or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab or nivolumab (second-line therapy)
Study: 33197225
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + ipilimumab (second-line and third-line therapy)
Study: 35942243
Drug: Yogurt with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt with Job's tears (200 ml daily)
Study: 35916505
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume ventilation (LTVV, Vt = 5 mL/kg along with 5 cm of H2O PEEP)
Study: 35916505
Drug: MCC950 (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCC950 (an inhibitor of NLRP3)
Study: 35916505
Drug: High-tidal-volume ventilation
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-tidal-volume ventilation (Vt = 10 mL/kg without PEEP)
Study: 32164792
Drug: LiuZiJue Qigong
Approvals — FDA: no, EMA: no, PMDA: no
Description: LiuZiJue Qigong (LQG) combined with conventional rehabilitation therapy
Study: 32164792
Drug: Traditional core
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional core stability training combined with conventional rehabilitation therapy
Study: 32595918
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g low-fat milk powder (placebo group)
Study: 34562781
Drug: Passive Seat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive Seat (new version of current passive air suspension seat)
Study: 33835597
Drug: Daily monetary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily monetary incentives + self-monitoring
Study: 33021044
Drug: Vilaprisan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan (2 mg) after high-fat, high-calorie meal
Study: 33021044
Drug: Vilaprisan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan (2 mg) after moderate-fat, moderate-calorie meal
Study: 33021044
Drug: Vilaprisan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan (2 mg) under fasting conditions
Study: 37074705
Drug: Tralokinumab 300
Normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab 300 mg
Study: 33813753
Drug: Zoledronate (ZOL)
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate (ZOL) administered 6 months after last denosumab
Study: 33813753
Drug: Zoledronate (ZOL)
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate (ZOL) administered 9 months after last denosumab
Study: 33369680
Drug: Behavioural‐based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural‐based physical activity intervention (12 weeks, 8 face-to-face sessions, 12 weekly phone calls, Fitbit tracking)
Study: 32542818
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day curcuminoids co‐administered with 5 mg/day piperine for 7 days
Study: 32406798
Drug: Hippotherapy intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hippotherapy intervention (12 weekly sessions)
Study: 34201686
Drug: Non-Steroidal Anti-Inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - loxoprofen (180 mg daily)
Study: 34201686
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of BVA and NSAIDs
Study: 35239083
Drug: Navigator ACT
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navigator ACT (Acceptance and Commitment Therapy group intervention)
Study: 34506241
Drug: Dexamethasone 0.4
Normalized name: dexamethasone 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.4 mg insert
Study: 34506241
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate 1% taper
Study: 35001412
Drug: Soticlestat 100-400
Normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat 100-400 mg QD
Study: 35001412
Drug: Soticlestat 600
Normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat 600 mg QD
Study: 35001412
Drug: Soticlestat 300
Normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat 300 mg BID
Study: 35160076
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no albumin administration)
Study: 34387216
Drug: Facilitated tucking
Normalized name: Tucks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated tucking with morphine (0.05‐mg/kg)
Study: 34387216
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with morphine (0.05‐mg/kg)
Study: 35225519
Drug: 0.3% nepafenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% nepafenac eye drops once daily for 4 weeks
Study: 32585278
Drug: Topical terbinafine
Normalized name: terbinafine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical terbinafine 10% solution (MOB-015)
Study: 32025254
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT), 8 sessions of 60 minutes each
Study: 32933950
Drug: Weight-based insulin
Normalized name: High molecular weight insulin human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weight-based insulin titration algorithm
Study: 32933950
Drug: Glucose-based insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-based insulin titration algorithm
Study: 39033046
Drug: Famotidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (20 mg)
Study: 33580103
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplement (10 mg iron, 10 mg zinc, 400 µg vitamin A)
Study: 32199882
Drug: Ustekinumab (anti-IL-12/IL-23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (anti-IL-12/IL-23 blockade) as induction and maintenance therapy
Study: 35385209
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg of anthocyanins (bilberry trihydroxy‐type)
Study: 35385209
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg of anthocyanins (black rice dihydroxy‐type)
Study: 35710926
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) on days 0, 3, 7, 14, and every 2 weeks thereafter (Group A)
Study: 35710926
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) every 3 weeks (Group B)
Study: 35864005
Drug: Daily motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily motivational messages sent via SMS for 21 days
Study: 32432339
Drug: BRV 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRV 100 mg/d
Study: 32432339
Drug: BRV 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRV 200 mg/d
Study: 36789515
Drug: Cariprazine 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 3.0 mg/day
Study: 35698087
Drug: Enhanced standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced standard treatment
Study: 35997125
Drug: V114 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: V114 vaccine
Study: 35071591
Drug: Iron proteinsuccinylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron proteinsuccinylate oral solution combined with vitamin A and D drops
Study: 35071591
Drug: Iron proteinsuccinylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron proteinsuccinylate oral solution (1.5 mL/kg)
Study: 34775240
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg two times daily + Mebeverine 135 mg three times daily
Study: 34149014
Drug: Oral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral appliance therapy for obstructive sleep apnoea (1-2 months duration)
Study: 34149014
Drug: Oral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral appliance therapy for obstructive sleep apnoea
Study: 34700258
Drug: enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: enhanced treatment as usual (eTAU)
Study: 33827837
Drug: PACT plus
Normalized name: Accu-Chek Compact Plus Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: PACT plus treatment as usual (TAU)
Study: 34373019
Drug: Subcutaneous pocket
Normalized name: POCKET CHAMBER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous pocket (SP) method
Study: 35501156
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg haloperidol
Study: 37838653
Drug: treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as usual (control)
Study: 34479242
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (50 mg/kg/single dose)
Study: 34479242
Drug: Aminophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (5 mg/kg/dose followed by continuous infusion at 1 mg/kg/hour for 3 hours)
Study: 36621408
Drug: MenACWY-TT (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-TT (1 dose)
Study: 36621408
Drug: MenACWY-TT (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-TT (2 doses)
Study: 36244640
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group of a trial of medication adherence reminder and symptom self-management intervention
Study: 32232410
Drug: NP213 (Novexatin®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP213 (Novexatin®) applied daily for 28 days
Study: 35279112
Drug: Opicapone (OPC)
DrugBank: Opicapone (DB11632)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Opicapone (OPC) 50 mg once daily
Study: 33066233
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (5-ASA) therapy
Study: 34551678
Drug: TDF/FTC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC + RAL (400 mg b.d.)
Study: 35032700
Drug: Affect Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Affect Management Treatment (AMT)
Study: 33980690
Drug: Target LDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target LDL cholesterol of 100 ± 10 mg/dL
Study: 33980690
Drug: Target LDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target LDL cholesterol of <70 mg/dL (in patients with diabetes)
Study: 33980690
Drug: Target LDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target LDL cholesterol of 100 ± 10 mg/dL (in patients with diabetes)
Study: 33980690
Drug: Target LDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target LDL cholesterol of <70 mg/dL (newly diagnosed diabetes)
Study: 33980690
Drug: Target LDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target LDL cholesterol of 100 ± 10 mg/dL (newly diagnosed diabetes)
Study: 32867047
Drug: 29 mL
Normalized name: ALCOHOL 20.3 mL in 29 mL EXTRACORPOREAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 29 mL of vinegar and 451 mL of water
Study: 32867047
Drug: 39 g
Normalized name: UREA 39 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 39 g of sucrose and 441 mL of water
Study: 32867047
Drug: 29 mL
Normalized name: ALCOHOL 20.3 mL in 29 mL EXTRACORPOREAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 29 mL of vinegar and 39 g of sucrose and 412 mL of water
Study: 32867047
Drug: 480 mL
Normalized name: urinary bag 480 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mL of water alone
Study: 32581204
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of esomeprazole twice daily (BD)
Study: 32581204
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of esomeprazole once daily (OD)
Study: 36177835
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure treatment
Study: 34323290
Drug: Fremanezumab monthly
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab monthly (225 mg at baseline, week 4, and week 8)
Study: 32930088
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) delivered via 13 out-patient sessions over 160 days
Study: 32930088
Drug: Person-Centred Experiential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Person-Centred Experiential Therapy (PCE) delivered via six out-patient sessions over 63 days
Study: 35233755
Drug: Trastuzumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab + chemotherapy vs trastuzumab monotherapy
Study: 34403780
Drug: Monthly newsletters
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly newsletters
Study: 33577365
Drug: Long-term androgen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term androgen deprivation therapy (LT-ADT) with calcium and vitamin D supplementation (CalVitD) (500 mg of Calcium BID + 400 IU of Vitamin D3 BID)
Study: 35111703
Drug: PHiD‐CV (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD‐CV (single dose)
Study: 35291434
Drug: Intravenous caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous caffeine (10 mg/Kg)
Study: 36164137
Drug: Isa-Kd (Isatuximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isa-Kd (Isatuximab 10 mg/kg IV weekly for 4 weeks, then every 2 weeks; Carfilzomib 20/56 mg/m2 twice weekly, 3/4 weeks)
Study: 34047291
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at 810 nm, 200 MW constant power, 30s irradiation time, energy dose of 6 J
Study: 33642694
Drug: Hybrid assistive
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid assistive limb treatment
Study: 33971037
Drug: Elobixibat plus
Normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Elobixibat plus 1-L PEG-Asc solution (group A)
Study: 33971037
Drug: Sodium picosulfate
Normalized name: Sodium Picosulfate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium picosulfate plus 1-L PEG-Asc solution (group B)
Study: 616037868
Drug: B&L Akreos
Approvals — FDA: no, EMA: no, PMDA: no
Description: B&L Akreos AO60
Study: 33979752
Drug: FreeStyle Navigator
Normalized name: LANCET,FREESTYLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: FreeStyle Navigator II subcutaneous CGM system from Abbott
Study: 33036588
Drug: Hydrocortisone dose
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone dose A (20 mg/10 mg)
Study: 33036588
Drug: Hydrocortisone dose
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone dose C (10 mg/5 mg)
Study: 83103622
Drug: Dithrocream (0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dithrocream (0.25% dithranol in vanishing cream)
Study: 35178150
Drug: Water treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water treatment (household chlorination with sodium hypochlorite)
Study: 35178150
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention (water treatment and handwashing)
Study: 33475184
Drug: C. zeylanicum
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. zeylanicum (0.5 mg/mL)
Study: 33475184
Drug: Nystatin (100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin (100,000 IU/mL)
Study: 32151146
Drug: DriSti intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DriSti intervention (partly tablet-administered, interactive)
Study: 33030035
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injection
Study: 32139102
Drug: Negative Pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative Pressure Wound Therapy (NPWT) with irrigation at 30 cc per hour
Study: 32139102
Drug: Negative Pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative Pressure Wound Therapy (NPWT) without irrigation
Study: 32139102
Drug: Negative Pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative Pressure Wound Therapy (NPWT) with irrigation
Study: 35470916
Drug: Crocin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocin (15 mg, twice daily)
Study: 32013681
Drug: Sodium control
Normalized name: Sodium chromate Cr-51
DrugBank: Sodium chromate Cr-51 (DB09380)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium control during post-dilution online hemodiafiltration treatments
Study: 33838536
Drug: Ultrasound-guided erector
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided erector spinae plane block with local anesthetic (10 mL of 1% lidocaine + 10 mL of 0.5% bupivacaine)
Study: 32556001
Drug: Mindfulness-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based intervention plus treatment as usual
Study: 38902546
Drug: UB-312 (300/300/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: UB-312 (300/300/300 μg)
Study: 32506371
Drug: Minocycline 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 400 mg orally twice a day with bevacizumab 10 mg/kg IV every two weeks and reirradiation
Study: 34649960
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention including brief telephone and print education, delivered in multiple languages, and personalized referral to a low-cost/free vaccine provider
Study: 33908377
Drug: Stimulant diversion
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant diversion prevention intervention